Dr. björn sörensen
He has extensive experience in international pharmaceutical development after almost 20 years in leading positions within the global pharmaceutical industry such as F. Hoffmann-LaRoche where he was responsible for the global clinical development of diabetes and cardiovascular. Nicholas Oakes holds a Ph. Jonas Faijerson Säljö has a research background in the stroke area with wide-ranging experience in the commercialization of medical innovations.
Jonas Faijerson Säljö holds a Ph. Fredrik Frick has extensive experience in research and development and 17 years of combined experience from working at AstraZeneca with early- to late-stage drug development including preclinical target identification, clinical drug discovery, clinical study management and operations and global project management of late-stage projects.
Fredrik Frick holds a Ph. Skilled professional in communications, investor relations and integrated marketing within life sciences and healthcare. Prior to that he was working as Vice President and responsible for the clinical development of cardiovascular and later gastrointestinal drugs at AstraZeneca. Previous experience includes working as an accountant at PWC, consultant at the accounting firm Arthur Andersen, and at companies of varying sizes across several dif- ferent industries.
Anders Svensson is independent of the Company, the Company management and of major shareholders as defined by the Swedish Code of Corporate Governance.
Zentrum für Allgemein-, Viszeral- und Thoraxchirurgie im Konzernverbund des Klinikums Nürnberg
Cereno Scientific is a pioneering clinical-stage biotech company developing innovative treatments to enhance and extend the lives of patients with diseases that have high unmet medical needs. Joakim is considered independent of the company, its management and major shareholders according to the Swedish corporate governance code. Björn Dahlöf has over 35 years of clinical experience added to his extensive experience in cardiovascular research, pharmacology, drug development, and clinical trials all phases and has lectured in these areas internationally.
Previous roles include management positions within developing technology companies as well as, most recently, heading up a boutique life science strategy advisory firm. Positive topline results from a Phase IIa trial were reported on September 27, CS is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator, beneath development for Idiopathic Pulmonary Fibrosis IPF. Drug candidate CS is an oral, highly potent and selective prostacyclin IP receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease.
Julia Fransson holds a B. Eva Jagenheim has a broad experience of various roles within finance. Born Joakim Söderström is an entrepreneur and biotech investor with experience as CEO, board member, and chairman. Rahul Agrawal is an experienced senior executive leader with a diverse background spanning Big Pharma and biotech. CS1 holds the potential to be an effective, safe and disease-modifying drug, targeting the root cause of the disease bygd reverse remodeling.
Björn Dahlöf has initiated and led several major national and multinational mortality and morbidity studies that have had significance for guidelines in cardiovascular prevention and authored over scientific publications. Faijerson Säljö has significant expertise in intellectual property and business development experience from a large number of companies in the life science area.
Navigation
Anders Svensson has almost publications to his name. While CS has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. Moreover, Joakim has previously held multiple managerial positions within the Swedish Police Authority. Specialized in public biotech companies headquartered in the Nordics.
He was a Board Member in Cereno Scientific between and has been a Member of the Scientific Advisory Board since this was established in Anders Svensson is a licensed physician, medical doctor, and lecturer with over 20 years of experience in academic medicine; his scientific focus fryst vatten cardiovascular diseases. Eva Jagnheim has a M. Nicholas Oakes has more than 20 years of experience working in the pharmaceutical industry with both efficacy and safety-related aspects of preclinical research to discover and develop new effective and safe medicines in metabolic, cardiovascular, and renal disease areas.
Øvlesen is independent of the company, the company management and of major shareholders as defined by the Swedish Code of Corporate Governance. Øvlesen has experience in business development and has been involved in more than 20 successful start-ups in medtech, biotech, and IT, including CLC Bio, Cetrea and Monsenso. Julia has experience from working with business development, strategy and valuation and in the life science industry both in operational, consultancy and investment settings.
Sten R. Sörensen has extensive experience from the pharma, biotech, and finance industries. Julia Fransson is an experienced business development professional in the life science industry. Adviser to small and large pharmaceutical companies regarding drug development in all phases from preclinical development to larger lifecycle management studies after registration. Cereno Scientific is a pioneering clinical-stage biotech company developing innovative treatments for diseases with high unmet medical needs.
Anders Svensson holds a MD, Ph. Founder of C Anders Svensson Consulting. At Monsanto and AstraZeneca, he initiated two groundbreaking preventive survival studies in heart failure, RALES and MERIT-HF, both establishing a paradigm shift for mineralocorticoid receptor MR antagonism and beta-blocker drug therapies in heart failure, significantly improving quality of life and life expectancy.